Total Payments
$201,569
2024 Payments
$48,783
Companies
23
Transactions
163
Medicare Patients
639
Medicare Billing
$110,347
Payment Breakdown by Category
Consulting$95,290 (47.3%)
Other$87,024 (43.2%)
Travel$15,481 (7.7%)
Food & Beverage$3,721 (1.8%)
Education$53.27 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $95,290 | 28 | 47.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $77,289 | 32 | 38.3% |
| Travel and Lodging | $15,481 | 45 | 7.7% |
| Honoraria | $9,735 | 4 | 4.8% |
| Food and Beverage | $3,721 | 51 | 1.8% |
| Education | $53.27 | 3 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ADC Therapeutics America, Inc. | $53,241 | 28 | $0 (2024) |
| Janssen Biotech, Inc. | $34,740 | 7 | $0 (2019) |
| Lilly USA, LLC | $34,638 | 27 | $0 (2024) |
| Epizyme, Inc. | $11,660 | 6 | $0 (2023) |
| Pharmacyclics LLC, An AbbVie Company | $10,791 | 16 | $0 (2019) |
| Regeneron Pharmaceuticals, Inc. | $9,560 | 13 | $0 (2024) |
| Celgene Corporation | $9,364 | 14 | $0 (2019) |
| Janssen Scientific Affairs, LLC | $8,340 | 13 | $0 (2019) |
| ABBVIE INC. | $6,196 | 5 | $0 (2023) |
| Ipsen Biopharmaceuticals, Inc | $4,979 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $48,783 | 34 | ADC Therapeutics America, Inc. ($18,136) |
| 2023 | $31,237 | 38 | Lilly USA, LLC ($17,372) |
| 2022 | $29,889 | 17 | ADC Therapeutics America, Inc. ($20,688) |
| 2021 | $22,682 | 13 | ADC Therapeutics America, Inc. ($10,571) |
| 2020 | $4,900 | 2 | Epizyme, Inc., ($2,950) |
| 2019 | $40,563 | 29 | Janssen Biotech, Inc. ($25,040) |
| 2018 | $17,546 | 23 | Celgene Corporation ($9,139) |
| 2017 | $5,968 | 7 | Janssen Biotech, Inc. ($5,500) |
All Payment Transactions
163 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $2,870.00 | General |
| 12/06/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $60.00 | General |
| Category: Oncology | ||||||
| 08/30/2024 | Ipsen Biopharmaceuticals, Inc | Tazverik (Drug) | Consulting Fee | Cash or cash equivalent | $4,920.00 | General |
| Category: Oncology | ||||||
| 08/20/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $138.02 | General |
| Category: Oncology | ||||||
| 06/05/2024 | ADC Therapeutics America, Inc. | — | Travel and Lodging | Cash or cash equivalent | $175.63 | General |
| 06/05/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | Cash or cash equivalent | $11.61 | General |
| 05/29/2024 | ADC Therapeutics America, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,840.00 | General |
| 05/24/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | Cash or cash equivalent | $124.01 | General |
| 05/22/2024 | ADC Therapeutics America, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $7,300.00 | General |
| 05/18/2024 | ADC Therapeutics America, Inc. | — | Travel and Lodging | Cash or cash equivalent | $237.48 | General |
| 05/17/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | Cash or cash equivalent | $108.88 | General |
| 05/16/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,500.00 | General |
| Category: Oncology | ||||||
| 05/16/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,575.00 | General |
| Category: Oncology | ||||||
| 05/14/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $672.64 | General |
| 05/14/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Food and Beverage | Cash or cash equivalent | $95.25 | General |
| Category: Oncology | ||||||
| 05/01/2024 | ADC Therapeutics America, Inc. | — | Travel and Lodging | Cash or cash equivalent | $688.20 | General |
| 03/11/2024 | ADC Therapeutics America, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,920.00 | General |
| 03/11/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,250.00 | General |
| Category: Oncology | ||||||
| 03/08/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,500.00 | General |
| Category: Oncology | ||||||
| 03/08/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,200.00 | General |
| Category: Oncology | ||||||
| 03/06/2024 | Kite Pharma, Inc. | — | Food and Beverage | In-kind items and services | $125.00 | General |
| 03/02/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $530.34 | General |
| 03/02/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $497.74 | General |
| 03/02/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $440.30 | General |
| 03/02/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $189.84 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 171 | 237 | $56,325 | $24,822 |
| 2022 | 5 | 189 | 321 | $68,704 | $31,269 |
| 2021 | 4 | 164 | 338 | $69,035 | $33,544 |
| 2020 | 5 | 115 | 218 | $49,313 | $20,712 |
Total Patients
639
Total Services
1,114
Medicare Billing
$110,347
Procedure Codes
17
All Medicare Procedures & Services
17 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 69 | 119 | $28,469 | $13,324 | 46.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 42 | 42 | $14,436 | $6,017 | 41.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 60 | 76 | $13,420 | $5,481 | 40.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 69 | 147 | $33,306 | $16,481 | 49.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 49 | 49 | $15,990 | $7,141 | 44.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 48 | 61 | $10,332 | $4,370 | 42.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 12 | 53 | $7,844 | $2,995 | 38.2% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2022 | 11 | 11 | $1,232 | $283.17 | 23.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 56 | 125 | $26,975 | $14,864 | 55.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 58 | 58 | $18,850 | $8,531 | 45.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 18 | 107 | $15,836 | $6,288 | 39.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 32 | 48 | $7,374 | $3,861 | 52.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 20 | 93 | $19,716 | $7,963 | 40.4% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 42 | 42 | $13,650 | $5,903 | 43.2% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 22 | 42 | $9,030 | $3,888 | 43.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 18 | 27 | $4,131 | $1,770 | 42.9% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2020 | 13 | 14 | $2,786 | $1,189 | 42.7% |
About Dr. Sameh Gaballa, MD
Dr. Sameh Gaballa, MD is a Medical Oncology healthcare provider based in Tampa, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/03/2008. The National Provider Identifier (NPI) number assigned to this provider is 1659534238.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sameh Gaballa, MD has received a total of $201,569 in payments from pharmaceutical and medical device companies, with $48,783 received in 2024. These payments were reported across 163 transactions from 23 companies. The most common payment nature is "Consulting Fee" ($95,290).
As a Medicare-enrolled provider, Gaballa has provided services to 639 Medicare beneficiaries, totaling 1,114 services with total Medicare billing of $110,347. Data is available for 4 years (2020–2023), covering 17 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Tampa, FL
- Active Since 07/03/2008
- Last Updated 07/02/2025
- Taxonomy Code 207RX0202X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1659534238
Products in Payments
- DARZALEX (Drug) $30,700
- IMBRUVICA (Drug) $12,363
- JAYPIRCA (Drug) $11,527
- Imbruvica (Drug) $10,791
- TAZVERIK (Drug) $9,735
- Tazverik (Drug) $6,904
- VENCLEXTA (Drug) $5,521
- Revlimid (Drug) $3,638
- Tecartus (Drug) $2,700
- BRUKINSA (Drug) $2,571
- POLIVY (Biological) $2,229
- Epkinly (Drug) $2,057
- CALQUENCE (Drug) $1,828
- UKONIQ (Drug) $1,800
- NO PRODUCT DISCUSSED (Drug) $400.00
- FOUNDATIONACT (Device) $308.56
- Rezlidhia (Drug) $39.34
- FOUNDATIONONE (Device) $27.63
- DARZALEX (Biological) $16.28
- MONJUVI (Drug) $14.88
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Tampa
Dr. Richard Kim, M. D, M. D
Medical Oncology — Payments: $844,688
Medical Oncology $844,688
Kenneth Shain, M.d, M.D
Medical Oncology — Payments: $394,889
Medical Oncology $394,889
Dr. Julio Chavez, Md, MD
Medical Oncology — Payments: $360,060
Medical Oncology $360,060
Ivan Borrello, M.d, M.D
Medical Oncology — Payments: $338,320
Medical Oncology $338,320
Dr. Jingsong Zhang, M.d, M.D
Medical Oncology — Payments: $254,025
Medical Oncology $254,025
Jonathan Strosberg, Md, MD
Medical Oncology — Payments: $207,211
Medical Oncology $207,211